Combined endothelin receptor antagonist and transcatheter interventional therapy of patent ductus arteriosus with severe pulmonary artery hypertension

Int J Cardiol. 2007 Apr 4;116(3):427-9. doi: 10.1016/j.ijcard.2006.03.080. Epub 2006 Jul 27.

Abstract

The natural history of congenital heart disease (CHD) with left to right shunt and high pulmonary blood flow, is characterized by development of severe Pulmonary Artery Hypertension (PAH); this condition usually contraindicates any type of surgical or interventional cardiac correction because of bad results. We here report the case of an adult patient with a patent ductus arteriosus and severe PAH, treated uneventfully with a staged combined therapy: Bosentan for 3 months and then percutaneous closure with amplatzer duct occluder (AGA Med. Co. Golden Valley, MN). The patient showed a dramatic improvement both of pulmonary hemodynamics and functional capacity at 8 months follow up confirming the efficacy of pulmonary vasodilator therapy in PAH associated to congenital heart disease.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antihypertensive Agents / therapeutic use*
  • Bosentan
  • Cardiac Catheterization*
  • Ductus Arteriosus, Patent / complications
  • Ductus Arteriosus, Patent / drug therapy
  • Ductus Arteriosus, Patent / therapy*
  • Endothelin Receptor Antagonists
  • Humans
  • Hypertension, Pulmonary / drug therapy
  • Hypertension, Pulmonary / etiology
  • Hypertension, Pulmonary / therapy*
  • Male
  • Middle Aged
  • Sulfonamides / therapeutic use*

Substances

  • Antihypertensive Agents
  • Endothelin Receptor Antagonists
  • Sulfonamides
  • Bosentan